Home > Insider Trading > Filing (0001209191-23-001932)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1706431	Vir Biotechnology Inc.	VIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1661908	Elliott Charles Sigal	C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-03	2,500	$25.60	2,500	No	4	P	Indirect	By Sigal Family Investments, LLC
Common Stock	Acquisiton	2023-01-04	2,500	$25.25	5,000	No	4	P	Indirect	By Sigal Family Investments, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Sigal Family Investments, LLC
No	4	P	Indirect	By Sigal Family Investments, LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,779	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.41 to $25.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.08 to $25.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.